This message was sent to the AIM, FAB, Health Systems, INE, IAP, LHD Health Officers, LHD Medical Directors, Biological Clerks, MACI, MACI 2, PH Imms Leads, MCIR Region Contacts, COVID-19 Vaccine Providers, and Imms All Staff listservs. Apologies for any duplication.

Dear Immunization Partners,

Please review the following COVID-19 vaccine update on the newly authorized Novavax COVID-19 vaccine, adjuvanted (2023-2024 Formula).

On October 3, 2023, the Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of Novavax COVID-19 Vaccine, Adjuvanted to include the 2023-2024 formula. The Novavax COVID-19 Vaccine, Adjuvanted (Original monovalent) is NO LONGER authorized for use in the United States.

Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) is authorized for use in individuals 12 years of age and older as follows:

• Individuals previously vaccinated with any COVID-19 vaccine: one dose of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) is administered at least 2 months after receipt of the last previous dose of an original monovalent (Original) or bivalent (Original and Omicron BA.4/BA.5) COVID-19 vaccine.
• Individuals not previously vaccinated with any COVID-19 vaccine: two doses of Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) are administered three weeks apart.
• As additional information is shared, we will send clinical guidance on immunocompromised individuals.

The Advisory Committee on Immunization Practice’s (ACIP) recommendation last month, which was then approved by the CDC director, was inclusive of all FDA-licensed or authorized updated 2023-2024 COVID-19 vaccines including the updated Novavax vaccine.

Additional information on allocations, ordering, and clinical guidance will be forthcoming as it is received by our Federal Partners.

For questions or assistance, please email: checcimms@michigan.gov 

Thank you for helping keep Michiganders healthy this fall and winter season!  
MDHHS Immunizations